ClinicalTrials.gg
RecruitingNCT07247110Updated Oct 30, 2026

A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)

A Phase 1 interventional study of MK-4716 and Pembrolizumab in Malignant Neoplasm, sponsored by Merck Sharp & Dohme LLC. Recruiting at 21 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

How we know · 8 judgments

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
250
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

Researchers are looking for new ways to treat certain advanced or metastatic solid tumors. The goal of this study is to learn about the safety of MK-4716 and if people tolerate it when taken alone or with other treatments.

02

Conditions studied

  • Malignant Neoplasm

Browse trials for

03

In context

Neoplasms

10,837 studies on the registry are indexed under Neoplasms; 2,323 are open to participants now.

This study's planned enrollment of 250 is above the median of 60 across 7,714 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subset of arm MK-4716 Dose Escalation and subset of arm MK-4716 + Cetuximab: Has a confirmed diagnosis of locally advanced unresectable or solid tumor
  • Subset of arm MK-4716 Dose Escalation and subset of arm MK-4716 + Cetuximab: Must demonstrate presence of Kirsten rat sarcoma viral oncogene homolog (KRAS) alteration
  • Subset of arm MK-4716 Dose Escalation and subset of arm MK-4716 + Cetuximab: Has received at least 1 for locally advanced unresectable or metastatic disease
  • Arm MK-4716 + Pembrolizumab: Has a confirmed diagnosis of metastatic non-small cell lung cancer
  • Arm MK-4716 + Pembrolizumab: Must demonstrate presence of KRAS alteration
  • Arm MK-4716 + Pembrolizumab: Must be untreated
  • Has
  • Has the ability to swallow and retain oral medication

Exclusion criteria

Exclusion Criteria:

  • Arm MK-4716 + Pembrolizumab: Has a diagnosis of immunodeficiency or is receiving chronic systemic therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of therapy within 7 days prior to the first dose of study intervention
  • Arm MK-4716 + Pembrolizumab: Has received any prior immunotherapy and was discontinued from that treatment
  • Arm MK-4716 + Pembrolizumab: Has active disease that has required systemic treatment in the past 2 years. Hormonal supplementation (eg, thyroxine, insulin, or physiologic corticosteroid) is allowed
  • History of infection
  • Has a known additional that is progressing or has required active treatment within the past 2 years
  • Has a known active central nervous system and/or carcinomatous meningitis
  • History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
  • Has active infection requiring systemic therapy
  • Has or virus infection
  • History of stem cell/solid organ transplant
  • Has not adequately recovered from major surgery or has ongoing surgical complications
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    MK-4716 Dose Escalation

    Participants receive MK-4716 at varying dose levels and schedules.

    Drug: MK-4716

  • Experimental
    MK-4716 + Pembrolizumab

    Participants will receive MK-4716 + Pembrolizumab

    Drug: MK-4716 · Biological: Pembrolizumab

  • Experimental
    MK-4716 + Cetuximab

    Participants will receive MK-4716 + Cetuximab

    Drug: MK-4716 · Biological: Cetuximab

Interventions

  • DrugMK-4716

    Oral administration

  • BiologicalPembrolizumab

    Intravenous administration

    Also known as: Keytruda, MK-3475

  • BiologicalCetuximab

    Intravenous administration

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLT)

    A DLT is defined as the occurrence of protocol-specified toxicities, unless clearly related to disease progression or intercurrent illness.

    Time frame: Up to approximately 28 days

  2. Number of Participants Who Experience an Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

    Time frame: Up to approximately 4 years

  3. Number of Participants Who Discontinue Study Intervention Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

    Time frame: Up to approximately 4 years

Secondary outcomes

  1. Area Under the Concentration-Time Curve (AUC) of MK-4716

    Blood samples will be collected to determine the AUC of MK-4716.

    Time frame: At designated timepoints (up to approximately 58 days)

  2. Maximum Plasma Concentration (Cmax) of MK-4716

    Blood samples will be collected to estimate Cmax of MK-4716.

    Time frame: At designated timepoints (up to approximately 58 days)

  3. Trough Plasma Concentration (Ctrough) of MK-4716

    Blood samples will be collected to determine the Ctrough of MK-4716.

    Time frame: At designated timepoints (up to approximately 19 months)

  4. Half-Life (t1/2) of MK-4716

    Blood samples will be collected to determine the t1/2 of MK-4716.

    Time frame: At designated timepoints (up to approximately 58 days)

07

Study locations

21 of 21 sites recruiting
  • Rutgers Cancer Institute of New Jersey ( Site 0052)
    New Brunswick, New Jersey 08903, United States
    Recruiting
    • Study Coordinator · Contact732-253-3939
  • NEXT Oncology ( Site 0051)
    Irving, Texas 75039, United States
    Recruiting
    • Study Coordinator · Contact972-893-8800
  • NEXT Virginia ( Site 0054)
    Fairfax, Virginia 22031, United States
    Recruiting
    • Study Coordinator · Contact703-783-4510
  • Blacktown Hospital ( Site 0455)
    Sydney, New South Wales 2148, Australia
    Recruiting
    • Study Coordinator · Contact98818000
  • Monash Health ( Site 0452)
    Clayton, Victoria 3168, Australia
    Recruiting
    • Study Coordinator · Contact+61474769510
  • The Alfred Hospital ( Site 0453)
    Melbourne, Victoria 3004, Australia
    Recruiting
    • Study Coordinator · Contact+61 3 9076 3129
  • One Clinical Research ( Site 0454)
    Nedlands, Western Australia 6009, Australia
    Recruiting
    • Study Coordinator · Contact+61862799466
  • Princess Margaret Cancer Centre ( Site 0001)
    Toronto, Ontario M5G 2M9, Canada
    Recruiting
    • Study Coordinator · Contact4165865371
  • Centre Hospitalier de l'Université de Montréal ( Site 0003)
    Montreal, Quebec H2X 0A9, Canada
    Recruiting
    • Study Coordinator · Contact5148908000
  • Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0002)
    Québec, Quebec G1J 1Z4, Canada
    Recruiting
    • Study Coordinator · Contact418-525-4444
  • FALP-UIDO ( Site 0101)
    Santiago, Region M. de Santiago 7500921, Chile
    Recruiting
    • Study Coordinator · Contact+56962290773
  • Pontificia Universidad Catolica de Chile-CICUC ( Site 0103)
    Santiago, Region M. de Santiago 8330073, Chile
    Recruiting
    • Study Coordinator · Contact+56934331806
  • Bradfordhill ( Site 0102)
    Santiago, Region M. de Santiago 8420383, Chile
    Recruiting
    • Study Coordinator · Contact+56229490970
  • Rambam Health Care Campus ( Site 0252)
    Haifa, 3109601, Israel
    Recruiting
    • Study Coordinator · Contact+97247772688
  • Rabin Medical Center ( Site 0253)
    Petah Tikva, 4941492, Israel
    Recruiting
    • Study Coordinator · Contact+97239377377
  • Sheba Medical Center ( Site 0251)
    Ramat Gan, 5265601, Israel
    Recruiting
    • Study Coordinator · Contact+97235303030
  • Seoul National University Hospital ( Site 0501)
    Seoul, 03080, South Korea
    Recruiting
    • Study Coordinator · Contact82-2-2072-0242
  • Asan Medical Center ( Site 0502)
    Seoul, 05505, South Korea
    Recruiting
    • Study Coordinator · Contact82-2-3010-1727
  • Hospital General Universitari Vall d Hebron ( Site 0360)
    Barcelona, 08035, Spain
    Recruiting
    • Study Coordinator · Contact+34932746000
  • Hospital Clinic de Barcelona ( Site 0362)
    Barcelona, 08036, Spain
    Recruiting
    • Study Coordinator · Contact+34932274208
  • Hospital Universitario Fundacion Jimenez Diaz ( Site 0361)
    Madrid, 28040, Spain
    Recruiting
    • Study Coordinator · Contact+34915504800x2805
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2030, 59 months after the start.

Of 676 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 61. This study's planned 59 months is above that.

Counting every sponsor, half of 903 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2025
First posted
Nov 25, 2025
StartActual
Dec 16, 2025
Primary completionEst.
Dec 1, 2030
CompletionEst.
Dec 1, 2030
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and references
1 update, last Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Minor edits only
    + 2 other changes: verification date and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07247110
Responsible party
Sponsor
First posted
Nov 25, 2025
Start date
Dec 16, 2025
Primary completion
Dec 1, 2030 (estimated)
Completion
Dec 1, 2030 (estimated)
Last update
Oct 30, 2026

Study contacts

Toll Free Number
Contact
Trialsites@msd.com
1-888-577-8839
Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion